±èÁÖÇ×
¾ÏÁ¤¹ÐÀÇ·á¼¾ÅÍÀå
¼Ò
¼Ó
: ºÐ´çÂ÷º´¿ø
Àü¹®ºÐ¾ß : Æó¾Ï, µÎ°æºÎ¾Ï, ½Äµµ¾Ï
Á÷
ˤ
: ±³¼ö(¾ÏÁ¤¹ÐÀÇ·á¼¾ÅÍÀå)
¸Þ
ÀÏ
:
ºñ°ø°³
Àü
È
:
1577-4488
ÆÑ
½º
:
ÁÖ
¼Ò
:
°æ±âµµ ¼º³²½Ã ºÐ´ç±¸ ¾ßžµ¿ 351¹øÁö
ȨÆäÀÌÁö:
ÅǸ޴º
ÁÖ¿ä¹ßÇ¥³í¹®
¹øÈ£
±¸ºÐ
Á¦¸ñ
´Ù¿î·Îµå
44
ÇØ¿Ü
Identical epidermal growth factor receptor mutations in adenocarcinomatous and squamous cell carcinomatous components of adenosquamous carcinoma of the lung
43
ÇØ¿Ü
Generation of a rabbit V-H domain antibody polyspecific to c-Met and adenoviral knob protein
42
ÇØ¿Ü
A phase II trial of fractionated irinotecan plus carboplatin for previously untreated extensive-disease small cell lung cancer
41
ÇØ¿Ü
Paclitaxel and leucovorin-modulated infusional 5-fluorouracil combination chemotherapy for metastatic gastric cancer.
40
ÇØ¿Ü
Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy
39
ÇØ¿Ü
Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model
38
ÇØ¿Ü
Markedly enhanced cytolysis by E1B-19kD-deleted oncolytic adenovirus in combination with cisplatin
37
ÇØ¿Ü
Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect
36
ÇØ¿Ü
The changes of estrogen receptor-¥â variants expression in breast carcinogenesis: Decrease of estrogen receptor-¥â2 expression is the key event in breast cancer development
35
ÇØ¿Ü
Comparison of stage-specific outcome of breast cancer based on 5th and 6th AJCC staging system
1
2
3
4
5
6
7
8
9
10
Copyright ¨Ï chamc, All rights reserved.
ºü¸£°í Æí¸®ÇÑ ÀÎÅÍ³Ý Áø·á¿¹¾à
Àüȹ®ÀÇ
°³²Â÷º´¿ø 02.3468.3000
ºÐ´çÂ÷º´¿ø 031.780.5000
Â÷¿ò 02.3015.5300
±¸¹ÌÂ÷º´¿ø 054.450.9700
´ë±¸¿©¼ºÂ÷º´¿ø 02.222.4200
°³²°ÇÁø¼¾ÅÍ 02.2191.3900
ºÐ´çÁ¾ÇÕ°Ç°ÁõÁø¼¾ÅÍ 031.780.5940
½ºÆ÷·º½º °ÇÁø¼¾ÅÍ 02.3473.2111
±¸¹ÌÂ÷º´¿ø°ÇÁø¼¾ÅÍ 054.450.9800
ȨÆäÀÌÁö°ü¸®ÀÚ 031.780.1729